You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Article metrics

Article menu

Download PDFPDF

Research Article
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2026

AbstractFullPdf
Dec 2019110
Jan 2020331
Feb 20201041041
Mar 2020772
Apr 202010101
May 202013131
Jun 202013130
Jul 202012125
Aug 2020880
Sep 202017172
Oct 202029290
Nov 202011110
Dec 202012121
Jan 2021773
Feb 202110101
Mar 2021881
Apr 2021552
May 202125254
Jun 202115151
Jul 202114146
Aug 2021461
Sep 202110103
Oct 202112134
Nov 202114144
Dec 202121215
Jan 202212133
Feb 202228308
Mar 202218185
Apr 202221257
May 202235351
Jun 202223230
Jul 202218193
Aug 202220202
Sep 202230325
Oct 202222221
Nov 2022151915
Dec 202215151
Jan 202322220
Feb 202338381
Mar 202320214
Apr 202314155
May 202313137
Jun 2023990
Jul 202315159
Aug 202316163
Sep 202316162
Oct 202344454
Nov 202346462
Dec 20231791798
Jan 202438396
Feb 202419192
Mar 202416166
Apr 202434343
May 202428281
Jun 202444435
Jul 202433356
Aug 202419186
Sep 202429295
Oct 202425255
Nov 202435364
Dec 202462621
Jan 202568689
Feb 20251021024
Mar 202523234
Apr 202534341
May 202530304
Jun 202535355
Jul 2025110
Sep 2025110
Mar 2026110
Total17511773222